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OBJECTIVE—Whereas an impaired ability to oxidize fatty acids
is thought to contribute to intracellular lipid accumulation,
insulin resistance, and cardiac dysfunction, high rates of fatty
acid oxidation could also impair glucose metabolism and func-
tion. We therefore determined the effects of diet-induced obesity
(DIO) in wild-type (WT) mice and mice deﬁcient for malonyl
CoA decarboxylase (MCD
/; an enzyme promoting mito-
chondrial fatty acid oxidation) on insulin-sensitive cardiac
glucose oxidation.
RESEARCH DESIGN AND METHODS—WT and MCD
/
mice were fed a low- or high-fat diet for 12 weeks, and intramyo-
cardial lipid metabolite accumulation was assessed. A parallel
feeding study was performed to assess myocardial function and
energy metabolism (nanomoles per gram of dry weight per
minute) in isolated working hearts (/– insulin).
RESULTS—DIO markedly reduced insulin-stimulated glucose
oxidation compared with low fat–fed WT mice (167  31 vs.
734  125; P  0.05). MCD
/ mice subjected to DIO displayed
a more robust insulin-stimulated glucose oxidation (554  82 vs.
167  31; P  0.05) and less incomplete fatty acid oxidation,
evidenced by a decrease in long-chain acylcarnitines compared
with WT counterparts. MCD
/ mice had long-chain acyl CoAs
similar to those of WT mice subjected to DIO but had increased
triacylglycerol levels (10.92  3.72 vs. 3.29  0.62 mol/g wet wt;
P  0.05).
CONCLUSIONS—DIO does not impair cardiac fatty acid oxida-
tion or function, and there exists disassociation between myo-
cardial lipid accumulation and insulin sensitivity. Our results
suggest that MCD deﬁciency is not detrimental to the heart in
obesity. Diabetes 58:1766–1775, 2009
T
he incidence of obesity, insulin resistance, and
diabetes is rapidly increasing (1–4), and by 2025
it is estimated that worldwide the incidence of
diabetes will affect nearly 333 million individuals
between 20 and 79 years of age (4). Obesity, insulin
resistance, and diabetes are characterized, at least in part,
by an elevation of circulating plasma fatty acid concentra-
tions. Whereas there is a general consensus that increased
circulating fatty acids lead to increased rates of fatty acid
uptake in muscle, the contribution of impaired mitochon-
drial fatty acid oxidation to the accumulation of cytosolic
intramuscular fatty acid metabolites implicated in the
pathogenesis of insulin resistance (such as long-chain acyl
CoAs, triacylglycerols, ceramides, and diacylglycerols) re-
mains controversial (5–8). It has been proposed that an
acceleration of mitochondrial fatty acid oxidation may
alleviate or attenuate skeletal muscle insulin resistance by
preventing the cytosolic accumulation of these fatty acid
metabolites (9,10).
We have recently demonstrated that insulin resistance
in response to high-fat feeding (diet-induced obesity
[DIO]) in skeletal muscle does not arise from an impair-
ment of mitochondrial fatty acid oxidation per se but
rather is associated with excessive rates of incomplete
fatty acid oxidation (11,12). DIO leads to an accumulation
of intramuscular long-chain acyl CoAs, the vast majority of
which are localized and oxidized in the mitochondria (13).
However, in the absence of high energy demand, often
observed in obese sedentary individuals, ﬂux through the
tricarboxylic acid (TCA) cycle is unable to increase to
such a rate to accommodate the large increase in acyl
CoAs oxidized. Interestingly, we also demonstrated in
mice that preventing the mitochondrial uptake of fatty
acids attenuates the development of fatty acid–induced
whole-body insulin resistance (11). This was achieved by
genetic deletion of malonyl CoA decarboxylase (MCD
/),
which degrades malonyl CoA, a potent endogenous inhib-
itor of the rate-limiting enzyme in mitochondrial fatty acid
uptake (carnitine palmitoyl transferase-1). A similar bene-
ﬁcial effect of MCD inhibition on insulin-stimulated glu-
cose metabolism in skeletal muscle cells was also
demonstrated recently (14). In our studies, MCD inhibition
was associated with a reduction in the accumulation of
long-chain acylcarnitines and a prevention in the down-
regulation of TCA cycle intermediates observed during
DIO (11). It can be argued that such a strategy would
increase the intramuscular accumulation of the aforemen-
tioned fatty acid metabolites (15). However, there was not
any increase in long-chain acyl CoAs and triacylglycerols
beyond that induced by high-fat feeding itself.
The accumulation of intramyocardial fatty acid metab-
olites is also implicated in mediating myocardial dysfunc-
tion (16,17). It is not clear what effect modifying fatty acid
oxidation has on insulin sensitivity in cardiac muscle.
Previous ﬁndings in the obese Zucker rat demonstrate an
impairment in fasting myocardial fatty acid oxidation
compared with lean controls, an effect accompanied by
elevated levels of intramyocardial lipid and an inability to
increase the expression of peroxisome proliferator–acti-
vated receptor (PPAR)- target genes (17). Conversely, we
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1766 DIABETES, VOL. 58, AUGUST 2009showed previously no difference in the rates of myocardial
fatty acid oxidation in either the fed or fasted states
between insulin-resistant JCR:LA-cp rats and lean controls
(18). Furthermore, in insulin-resistant JCR:LA-cp rats there
was nearly a doubling in myocardial triacylglycerol
stores, supporting the observation that the accumulation
of intramyocardial fatty acid metabolites is the result of
excessive fatty acid supply, opposed to impaired fatty acid
oxidation. Also, we have demonstrated that myocardial
fatty acid oxidation rates are elevated in transgenic PPAR-
–overexpressing mice, a phenotype resembling that of
type 2 diabetes (19). Therefore, debate still exists with
regards to the accumulation of fatty acid metabolites, fatty
acid oxidation rates, and myocardial insulin resistance.
In this study, we investigated the relationship between
myocardial fatty acid metabolite accumulation, fatty acid
oxidation, and insulin-stimulated glucose oxidation in
wild-type (WT) and MCD
/ mice fed either low- or
high-fat diet. We hypothesized that inhibition of mitochon-
drial fatty acid uptake via ablation of MCD preserves
insulin-sensitive myocardial glucose oxidation, despite el-
evated levels of intramyocardial long-chain acyl CoAs and
triacylglycerols.
RESEARCH DESIGN AND METHODS
An expanded RESEARCH DESIGN AND METHODS section is available in the online
appendix at http://diabetes.diabetesjournals.org/cgi/content/full/db09-0011/
DC1. Details on isolated working heart perfusions, ultrasound echocardiog-
raphy, metabolic proﬁling, high-energy phosphate assessment, pyruvate
dehydrogenase (PDH) activity, and immunoblot analysis is also provided in
the online appendix.
All animals received care according to the Canadian Council on Animal
Care and the University of Alberta Health Sciences Animal Welfare Commit-
tee. Twelve-week-old WT or MCD
/ mice were placed on a standard
chow/low-fat diet (4% kcal from lard) or high-fat diet (60% kcal from lard;
Research Diets, D12492) for a 12-week period. At the end of week 12, animals
were killed via an intraperitoneal injection of sodium pentobarbital (12 mg)
either in the fed state in the middle of the dark cycle or after a 6-h fast. Hearts
were excised and immediately frozen in liquid N2 for biochemical analyses or
perfused in the isolated working mode (see online appendix).
RESULTS
Effects of DIO on cardiac fatty acid and glucose
oxidation in isolated working mouse hearts. Subject-
ing mice to a 12-week period of DIO did not result in any
alteration in isolated working heart function compared
with low fat–fed mice (Table 1). Of interest is that cardiac
function was also normal in MCD
/ mice regardless of
whether they were obtained from the low fat–fed or DIO
group. This demonstrates that MCD deﬁciency does not
contribute to cardiac dysfunction in DIO mice. Reinforcing
our ex vivo perfusion data, we also showed via ultrasound
echocardiography that in vivo cardiac function was unal-
tered by DIO in WT or MCD
/ mice (Table 2). Despite the
lack of functional changes, dramatic differences in cardiac
energy metabolism were observed between the experi-
mental groups. Hearts from WT mice subjected to DIO had
a signiﬁcant reduction in glucose oxidation rates com-
pared with low fat–fed mice, with no change in oxidation
of exogenously supplied [9,10-
3H]palmitate (Fig. 1B). In-
sulin (100 U/ml) robustly stimulated myocardial glucose
oxidation in low fat–fed WT mice (Fig. 1A) and decreased
fatty acid oxidation (Fig. 1B). In contrast, insulin had only
a small effect on glucose oxidation in WT DIO mice (Table
3), demonstrating an impaired insulin-stimulated glucose
metabolism in these DIO hearts.
Insulin stimulation of glucose oxidation was signiﬁ-
cantly increased in MCD
/ mice compared with WT mice
in both the low fat–fed and DIO groups (Fig. 1A). This was
accompanied by a signiﬁcant decrease in fatty acid oxida-
tion in low fat–fed MCD
/ mice and a small nonsigniﬁ-
cant decrease in fatty acid oxidation in MCD
/ DIO mice,
which may be attributed to a trend toward lower fatty acid
oxidation rates in the absence of insulin (Fig. 1B). As such,
the contribution of glucose oxidation for acetyl CoA
production was signiﬁcantly increased whereas the con-
tribution of fatty acid oxidation for acetyl CoA production
was signiﬁcantly decreased in MCD
/ DIO mice, illustrat-
TABLE 1
MCD deﬁciency does not result in ex vivo cardiac dysfunction following DIO
WT (LF) MCD
/ (LF) WT (DIO) MCD
/ (DIO)
Cardiac output (ml/min) 8.3  1.0 11.3  1.1 11.2  0.9 10.8  0.3
Cardiac work (ml   mmHg
1   min
1) 5.3  0.8 7.4  0.9 7.0  0.5 6.9  0.5
Data are means  SE. Parameters of cardiac function (cardiac output and cardiac work) were assessed in isolated working hearts obtained
from WT and MCD
/ mice subjected to either a low-fat diet (LF) or DIO (n  5–7).
TABLE 2
MCD deﬁciency does not result in in vivo cardiac dysfunction following DIO
WT (LF) MCD
/ (LF) WT (DIO) MCD
/ (DIO)
Tei index 0.42  0.02 0.44  0.02 0.45  0.08 0.46  0.04
Cardiac output (ml/min) 23.89  3.16 24.60  2.12 26.19  2.10 23.07  0.71
LVPW:d (mm) 0.74  0.02 0.83  0.06 0.87  0.02* 0.81  0.01
LVID:d (mm) 4.10  0.10 4.27  0.08 4.32  0.04 4.21  0.03
LVPW:s (mm) 1.04  0.03 1.06  0.07 1.23  0.03* 1.07  0.02†
LVID:s (mm) 2.78  0.14 3.06  0.15 2.72  0.07 2.96  0.05
Body weight (g) 26.33  0.99 28.44  1.78 41.33  0.54 39.68  1.86
LV mass (g) 0.16  0.01 0.17  0.01 0.22  0.02 0.22  0.01
LV mass/body weight 0.60  0.01 0.59  0.01 0.54  0.07 0.57  0.04
Data are means  SE. In vivo cardiac function and ventricular wall measurements were assessed via ultrasound echocardiography
(VisualSonics; Vevo 770) in isoﬂurane-anesthetized WT and MCD low-fat diet (LF) and DIO mice (n  5–12). *P  0.05 indicates a signiﬁcant
difference from low-fat diet counterpart. †P  0.05 indicates a signiﬁcant difference from WT DIO mice. d, diastole; s, systole; LVID, left
ventricular internal diameter; LVPW, left ventricular posterior wall.
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metabolism versus their WT counterparts (Fig. 1C). Para-
lleling our earlier work in MCD
/ mice whereby compen-
satory increases in PPAR- target gene mRNA expression
could explain the lack of change in myocardial fatty acid
oxidation rates in MCD
/ mice, we show that MCD
/ DIO
hearts had higher PPAR- target gene pyruvate dehydroge-
nase kinase (PDK)-4 protein expression (Fig. 2A). Despite
this elevation in PDK4 expression, total PDH activity and the
active state of PDH were signiﬁcantly higher in hearts from
MCD
/ DIO mice, but the ratio of active to total PDH
activity remained the same in both groups (Fig. 2B and D).
Nonetheless, these ﬁndings demonstrate that decreasing
MCD can partially overcome the dramatic impairment in
insulin-stimulated glucose metabolism seen with DIO, which
may be due to a preservation of PDH activity.
Effects of DIO and fasting on cardiac malonyl CoA
levels. Because malonyl CoA is a major regulator of
cardiac fatty acid oxidation, we examined what effect DIO
had on cardiac malonyl CoA levels. Shown in Fig. 3, DIO
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FIG. 1. MCD deﬁciency improves insulin-stimulated glucose oxidation
in DIO mice. A: DIO lead to an impairment in insulin-stimulated glucose
oxidation in hearts from WT mice ( ) that was prevented in hearts
from MCD
/ mice (f). B: Rates of fatty acid oxidation did not differ in
hearts from WT ( ) and MCD
/ (f) mice. C: However, the contribu-
tion of myocardial fatty acid oxidation rates to acetyl CoA production
was decreased in MCD
/ DIO versus WT DIO mice.  , Glucose
oxidation; f, fatty acid oxidation. Values represent means  SE (n 
5–7). Differences were determined using a repeated-measures ANOVA.
*P < 0.05, signiﬁcantly different from low-fat counterpart. †P < 0.05,
signiﬁcantly different from insulin-negative counterpart. ‡P < 0.05,
signiﬁcantly different from insulin-positive high-fat WT.
TABLE 3
MCD deﬁciency results in an improved myocardial insulin sensi-
tivity index following DIO
WT (LF)
MCD
/
(LF) WT (DIO)
MCD
/
(DIO)
Insulin
sensitivity 734  125 1,351  23 167  31 554  82*
Data are means  SE. Insulin sensitivity index was calculated as the
absolute increase (	 with insulin  without insulin
) in glucose
oxidation (nanomoles per gram of dry weight per minute) in re-
sponse to insulin (100 U/ml) treatment in hearts obtained from WT
and MCD
/ mice (n  5–7). *P  0.05 indicates a signiﬁcant
difference from WT DIO mice. LF, low-fat diet.
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FIG. 2. MCD deﬁciency improves PDH activity in DIO mice despite an
increased expression of PDK4. A: MCD
/ DIO mice had an increased
expression of the PPAR target gene PDK4. B: The active portion of the
PDH complex was higher in MCD
/ DIO mice. C: Total PDH activity
was also higher in MCD
/ DIO mice. D: However, the percentage of
active PDH did not differ between MCD
/ DIO and WT DIO mice.
Values represent means  SE (n  6). Differences were determined
using a Student’s two-tailed t test. *P < 0.05, signiﬁcantly different
from WT DIO mice.
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with low fat–fed WT mice. As expected, MCD
/ mice
subjected to DIO showed a signiﬁcant increase in malonyl
CoA levels compared with WT DIO mice (Fig. 3). In addition,
malonyl CoA levels from fasted WT mice did not differ from
their fed counterparts but were signiﬁcantly lower than those
in fasted MCD
/ mice (supplemental Fig. 1A).
Effects of DIO and fasting on myocardial long-chain
acylcarnitine levels. Following 12 weeks of low-fat feed-
ing or DIO, there was a signiﬁcant reduction in the
accumulation of a number of long-chain acylcarnitine
species in hearts from MCD
/ mice compared with hearts
from WT littermates (Fig. 4A–D). In addition, medium-
chain fatty acids do not require carnitine palmitoyl trans-
ferase (CPT)-1 for entry into the mitochondria, and as
such no changes in any medium-chain acylcarnitine spe-
cies were observed in hearts of MCD
/ DIO mice versus
WT DIO mice, except the C10:3 species (4.4  1.3 vs.
15.8  4.1 pmol C10:3 acylcarnitine/mg protein, P  0.05;
data not shown). These ﬁndings are consistent with an
inhibition of CPT1 and a lowering of intramitochondrial
fatty acid oxidation intermediates.
In another group, following 12 weeks of low-fat feeding,
mice were fasted for 6 h prior to the analysis of myocardial
long-chain acylcarnitines, and similar to our DIO ﬁndings,
we report that long-chain acylcarnitines do not accumu-
late to the same extent in hearts from fasted MCD
/ mice
versus their WT counterparts (supplemental Fig. 1B). The
medium-chain acylcarnitine proﬁle from fasted mice also
paralleled our DIO ﬁndings in which no accumulation was
observed except for the C10:3 species (4.8  2.2 vs. 17.9 
2.0 pmol C10:3 acylcarnitine/mg protein, P  0.05; data not
shown), consistent with no CPT-1 requirement for mito-
chondrial oxidation of medium-chain fatty acids. Interest-
ingly, the fasting-induced increase in -hydroxybutyrl
(C4-OH) carnitine was prevented in the MCD
/ group
(223.9  20.8 vs. 104.2  12.7 pmol -hydroxybutyrl
carnitine/mg protein, P  0.05; data not shown), paralleling
what we have previously reported in skeletal muscle (11).
Myocardial TCA cycle intermediates are not depleted
by DIO or fasting. Previous work in skeletal muscle has
suggested that fatty acid overload in response to fasting or
DIO results in incomplete fatty acid oxidation by causing a
disconnect between fatty acid oxidation and the TCA
cycle, an effect prevented by the genetic deletion of MCD
(11). Interestingly, myocardial short-chain CoAs and TCA
cycle intermediates were not depleted by either fasting
(data not shown) or DIO (Fig. 4E and F)i nW To rM C D
/
groups, contrasting what we have reported previously in
skeletal muscle. This likely reﬂects the higher acetyl CoA
production from glucose oxidation in the MCD
/ mice;
however, total acetyl CoA production from both glucose
and palmitate was signiﬁcantly depressed in WT DIO mice,
indicative of mitochondrial impairment (Table 4). More-
over, deﬁciency of MCD, although associated with a
reduced contribution of fatty acids for acetyl CoA produc-
tion, did not impair mitochondrial function in lean mice
and did not exacerbate the impairment observed in DIO
WT mice. AMP (0.37  0.08 vs. 0.41  0.06 mol/g dry wt
in WT and MCD
/ low fat–fed mice and 0.31  0.05 vs.
0.33  0.03 mol/g dry wt in WT and MCD
/ DIO mice)
and ATP (1.89  0.15 vs. 1.81  0.35 mol/g dry wt in WT
and MCD
/ low fat–fed mice and 1.63  0.11 vs. 1.77 
0.27 mol/g dry wt in WT and MCD
/ DIO mice) levels
were also not altered between any of the experimental
groups, consistent with normal TCA cycle activity in these
hearts. Myocardial lactate and pyruvate levels were also
measured and showed no changes, regardless of diet,
between WT and MCD
/ mice (Table 5).
Intramyocardial long-chain acyl CoA and triacylglyc-
erol content following DIO or fasting. It has been
suggested that an impairment in the mitochondrial
uptake and subsequent oxidation of fatty acids contrib-
ute to the accumulation of intramuscular acyl CoAs and
the development of insulin resistance (6,8,15) and myocar-
dial dysfunction (16,17,20). Therefore, we investigated the
effects of DIO on the myocardial accumulation of acyl
CoAs. In low fat–fed mice, MCD deﬁciency did not alter
the levels of the major long-chain acyl CoAs or total
long-chain acyl CoAs compared with those in WT mice
(Fig. 5A). DIO resulted in a marked increase in the major
cardiac long-chain acyl CoAs and total long-chain acyl
CoAs in WT mice compared with low fat–fed mice (Fig.
4A). DIO signiﬁcantly increased intramyocardial long-
chain acyl CoA levels to similar extents in MCD
/ mice
compared with WT mice (Fig. 5A). This demonstrates
dissociation between long-chain acyl CoA accumulation
and insulin sensitivity in DIO mice.
MCD deﬁciency did not alter myocardial triacylglycerol
levels in low fat–fed mice (Fig. 5B). However, a signiﬁcant
increase in triacylglycerol levels was seen in the DIO
MCD
/ mice compared with WT DIO mice. This again
demonstrates a disassociation between accumulation of
triacylglycerol and insulin resistance in DIO hearts.
Because accumulation of ceramide has also been impli-
cated in cardiac lipotoxicity, we measured ceramide levels
in WT and MCD
/ mice subjected to DIO (Fig. 5C). No
difference was observed in ceramide levels between DIO
and low fat–fed mice in either the WT or MCD
/ groups.
Low fat–fasted WT and MCD
/ mice showed results
similar to those of DIO WT and MCD
/mice in that a similar
accumulation in long-chain acyl CoA and no accumulation in
ceramide were observed. Furthermore, myocardial triacyl-
glycerol levels once again did not accumulate in fasted WT
mice but did accumulate in fasted MCD
/ mice (8.42  1.28
vs. 3.72  0.68 mol/g wet wt, P  0.05; data not shown).
Effects of DIO on expression and phosphorylation of
proteins involved in regulating myocardial energy
metabolism and insulin signaling. Several proteins in-
cluding PPAR- coactivator 1 (PGC1-) and uncoupling
protein 2 (UCP2) have been proposed to be altered by DIO
in both skeletal and cardiac muscle (12,21–24). Neither the
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FIG. 3. MCD deﬁciency increases myocardial malonyl CoA levels in DIO
mice. Malonyl CoA levels were higher in MCD
/ (f) than WT ( ) mice
following low-fat diet or DIO. Values represent means  SE (n  4–5).
Differences were determined using a two-way ANOVA followed by
Bonferroni post hoc analysis. *P < 0.05, signiﬁcantly different from
diet-matched WT mice.
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altered by DIO in either the WT or MCD
/ groups.
Supporting improved cardiac insulin sensitivity in MCD
/
DIO mice, we demonstrate an increase in Akt serine 473
phosphorylation and a trend to an increased glycogen syn-
thase kinase 3 serine 9 phosphorylation in MCD
/ DIO
hearts (P  0.09) perfused aerobically with insulin (Fig. 7A
and B). Insulin had no effect on 5
AMP-activated protein
kinase (AMPK) phosphorylation at threonine 172 (Fig. 7C),
suggesting that AMPK likely does not play a role in the
improved insulin sensitivity observed in MCD
/ DIO hearts.
DISCUSSION
This study provides a number of important novel ﬁndings
regarding the effects of DIO on cardiac insulin sensitivity.
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FIG. 4. MCD deﬁciency decreases the accumulation of fatty acid oxidative intermediates in DIO mice without decreasing TCA cycle intermediates.
MCD
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/ mice subjected to DIO did not alter myocardial
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/ mice subjected to DIO did not have alterations in myocardial TCA cycle intermediates
compared with WT DIO mice. Values represent means  SE (n  5–11). Differences were determined using a two-way ANOVA followed by
Bonferroni post hoc analysis. *P < 0.05, signiﬁcantly different from WT low fat–fed mice. †P < 0.05, signiﬁcantly different from WT DIO. □,
Wild-type low fat; p, wild-type high fat; , MCD
/ low fat; f, MCD
/ high fat.
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ment in insulin-stimulated glucose metabolism in mouse
hearts; 2) increasing malonyl CoA levels in the heart
secondary to deletion of MCD can prevent this impair-
ment; 3) the DIO-induced impairment in cardiac insulin-
stimulated glucose metabolism can be dissociated from
the accumulation of myocardial lipid intermediates, con-
tradicting what has been previously proposed in skeletal
muscle; 4) similar to recent evidence in skeletal muscle
(11), this impairment in insulin-stimulated glucose metab-
olism correlates with the accumulation of intermediates of
incomplete fatty acid oxidation; and 5) the insulin-sensi-
tizing effects of MCD deletion are accompanied by a
decrease in the accumulation of fatty acid intermediates of
incomplete fatty acid oxidation. These data provide impor-
tant insights into the pathophysiology of cardiac insulin
resistance and suggest that inhibition of fatty acid oxida-
tion (as opposed to stimulation of fatty acid oxidation)
may have therapeutic potential in preventing obesity-
induced impairments on cardiac insulin-stimulated glu-
cose metabolism.
In skeletal muscle, two opposing views of how high
fat–induced insulin resistance occurs have been proposed.
A widely cited hypothesis is that the accumulation of
cytoplasmic fatty acid intermediates impairs insulin sig-
naling (6,8,15). Based on this hypothesis, it has been
proposed that stimulation of fatty acid oxidation can lower
these intermediates and improve insulin sensitivity. How-
ever, recent studies by us (11) and others (14) have
challenged this concept. Recent studies have suggested
that accumulation of intermediates of incomplete fatty
acid oxidation correlate with skeletal muscle insulin resis-
tance (11,25,26). Of importance is that inhibition of fatty
acid oxidation secondary to MCD deletion resulted in an
TABLE 4
Insulin-stimulated cardiac acetyl CoA production in WT and MCD
/ mice following DIO
WT (LF) MCD
/ (LF) WT (DIO) MCD
/ (DIO)
Acetyl CoA production from glucose oxidation
(nmol   g dry wt
1   min
1) 2,491  397 4,023  181 811  71* 1,888  159*†
Acetyl CoA production from palmitate oxidation
(nmol   g dry wt
1   min
1) 1,868  567 1,629  284 2,471  252 1,866  104
Total acetyl CoA production (glucose  palmitate)
(nmol   g dry wt
1   min
1) 4,522  464 5,652  416 3,282  216* 3,702  192*
Data are means  SE. Insulin-stimulated cardiac acetyl CoA production was determined by multiplying the glucose oxidation rate by 2 and
the palmitate oxidation rate by 8. These values were used to determine the overall percent contribution to TCA cycle acetyl CoA production
in hearts obtained from WT and MCD
/ mice (n  5–7). *P  0.05 indicates a signiﬁcant difference from low-fat diet (LF) counterpart. †P 
0.05 indicates a signiﬁcant difference from WT DIO mice.
TABLE 5
Myocardial lactate and pyruvate content in WT and MCD low-fat
diet and DIO mice
Lactate Pyruvate
Lactate 
pyruvate
Lactate/
pyruvate
LF
WT 223.1  27.6 8.0  3.3 231.2  29.5 43.9  12.1
MCD
/ 255.9  46.6 4.6  0.9 260.5  46.6 71.8  18.3
DIO
WT 215.5  18.5 6.6  1.0 221.1  19.1 35.8  6.4
MCD
/ 172.4  23.4 25.4  11.7 197.8  22.8 17.7  10.0
Data are means  SE. Lactate and pyruvate content (nanomoles per
milligram of protein) were assessed during the dark cycle in the fed
state in hearts obtained from WT or MCD
/ mice on either a low-fat
diet (LF) or subjected to DIO (n  5–11).
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FIG. 5. Improvement of insulin senstivity in MCD
/ mice subjected to
DIO does not correlate with the accumulation of myocardial lipid
intermediates. A: DIO increased long-chain acyl CoAs to similar ex-
tents in both WT and MCD
/ mice. B: Triacylglycerols only accumu-
lated in MCD
/ mice following DIO and did not accumulate in WT
mice. C: Ceramides do not accumulate following DIO in hearts from WT
and MCD
/ mice. Values represent means  SE (n  4–11). Differ-
ences were determined using a two-way ANOVA followed by Bonferroni
post hoc analysis. *P < 0.05, signiﬁcantly different from low fat–fed
counterpart. f, MCD
/;  , WT.
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via glucose/insulin tolerance testing, fasting plasma glu-
cose levels, and indirect calorimetry (11). Using siRNA to
knockdown MCD in skeletal muscle cells also results in an
increase in insulin-stimulated glucose metabolism (14). In
this study we show a similar beneﬁcial effect of MCD
deletion in cardiac muscle. MCD
/ mice subjected to DIO
showed a signiﬁcant improvement in insulin-stimulated
cardiac glucose oxidation and insulin signaling at the level
of Akt phosphorylation. This was associated with a de-
creased accumulation of a number of long-chain acyl
carnitine species in response to DIO. These data clearly
suggest that stimulation of cardiac fatty acid oxidation
would not be desirable in preventing the impairment in
insulin-stimulated glucose metabolism seen with DIO.
The preservation of insulin-stimulated glucose oxidation
in hearts from MCD
/ mice may be due to increases in
both active and total PDH activity versus that observed in
the WT littermate controls. Interestingly, the percentage of
active PDH versus total PDH activity remained the same in
both MCD
/ and WT DIO hearts. However, the fact that
both the active portion and total activity of PDH are higher
in the MCD
/ DIO hearts likely explains the preservation
of insulin-stimulated glucose oxidation rates in these mice.
Surprisingly, we only observed a trend to a reduction in
fatty acid oxidation rates in hearts from MCD
/ mice,
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size that the fatty acid oxidation assay utilized in this study
only measures oxidation of a single exogenously supplied
fatty acid ([9,10-
3H]palmitate). Unfortunately, the assay
does not account for incomplete fat oxidation, oxidation
of endogenously supplied fatty acids, and oxidation of
other fatty acid species (oleate, stearate, etc.). By compar-
ison, the intramyocardial acylcarnitine measurements pro-
vide more comprehensive information. The acylcarinitine
proﬁle revealed that MCD deﬁciency had a greater impact
on the accumulation of oleyl-carnitine (C18:1), stearoyl-
carnitine (C18:0), linoleyl-carnitine (C18:2), and tetradeca-
dienoyl-carnitine (C14:2) as compared with palmitoyl-
carnitine (C16:0). Coupled together with the observation
that ATP and acetyl CoA levels were similar between
nonperfused WT and MCD
/ DIO hearts, despite greater
glucose oxidation rates in MCD
/ DIO hearts, it is highly
suggestive that fatty acid oxidation is greater in the hearts
of WT mice.
In this study DIO increased long-chain acyl CoA levels
without affecting triacylglycerol or ceramide levels in
hearts from WT mice. MCD deletion did not exacerbate
the increase in long-chain acyl CoA levels in DIO mice but
did result in an increase in triacylglycerol levels compared
with WT DIO mice. DIO increased triacylglycerols in
hearts from MCD
/ mice. Whereas DIO severely attenu-
ated insulin-stimulated glucose oxidation in hearts from
WT mice, hearts from MCD
/ mice were protected from
this decrement. These data demonstrate a clear dissocia-
tion between myocardial lipid accumulation and insulin
resistance in DIO. The DIO-induced alterations in myocar-
dial fatty acid metabolite accumulation and insulin-stimu-
lated glucose oxidation also occurred independently of
changes in the expression of PGC1- or UCP2 or the
expression and phosphorylation of AMPK. These data
indicate that inhibition of the mitochondrial uptake of
fatty acids via ablation of MCD does not exacerbate the
accumulation of intramyocardial fatty acyl carnitines or
fatty acyl CoAs and does not induce insulin resistance or
myocardial dysfunction. Rather, ablation of MCD prevents
the accumulation of intramyocardial acylcarnitines likely
by increasing the esteriﬁcation of available intracellular
fatty acids into triacylglycerols, thereby alleviating the
detrimental effects of DIO on cardiac insulin-stimulated
glucose metabolism.
Supporting our ﬁndings, studies in mice with a cardiac-
speciﬁc overexpression of PPAR- demonstrate an eleva-
tion in cardiac fatty acid oxidation rates and possess a
phenotype mimicking that seen in type 2 diabetes (19).
These animals have a dramatic impairment in insulin-
stimulated glucose oxidation and show a reduction in
18F-ﬂuorodeoxyglucose uptake via positron emission to-
mography imaging. Furthermore, genetic ablation of the
fatty acid transporter CD36 in these animals restored the
impairment in glucose oxidation rates, with a strong trend
to a reduction in oxidation of exogenously supplied palmi-
tate (27). Elegant studies by Aasum et al. (28) also parallel
our ﬁndings, where DIO mice and leptin receptor–deﬁ-
cient (db/db) diabetic mice have a dramatic impairment in
insulin-stimulated glucose oxidation rates (29). Peripheral
activation of PPAR- in DIO mice with fenoﬁbrate im-
proved whole-body glucose tolerance and myocardial
recovery from ischemia/reperfusion injury while signiﬁ-
cantly increasing hepatic fatty acid oxidation rates (28).
However, myocardial fatty acid oxidation rates were sig-
niﬁcantly reduced, and this was associated with a com-
plete restoration of glucose oxidation rates. Treatment of
db/db mice with the PPAR- agonist rosiglitazone pro-
duced a similar effect, reducing myocardial fatty acid
oxidation rates and restoring glucose oxidation rates to
those seen in db/ lean nondiabetic control mice, which
was also associated with protection against myocardial
ischemia/reperfusion injury (29).
Interestingly, in contrast to skeletal muscle (11), there
was not an accompanying depletion of TCA cycle interme-
diates in hearts from WT mice subjected to DIO compared
with low fat–fed WT mice. We also did not observe any
differences in total high-energy phosphates between
groups. This discrepancy may be related to the marked
increase in acetyl CoA derived from glucose oxidation in
the MCD
/ mice hearts, which may exceed that seen in
skeletal muscle (Table 3). Furthermore, potential differ-
ences in the anaplerotic capacity of cardiac and skeletal
muscle may also partially account for this difference.
Pyruvate carboxylation is an important anaplerotic reac-
tion in cardiac muscle (30), and the relative abundance of
pyruvate carboxylase is greater in cardiac versus skeletal
muscle (31). Taken together these differences may, by
mass action, replenish the TCA cycle at the level of malate
and oxaloacetate (32–34) and thus account for the lack of
TCA cycle intermediate depletion in response to fasting or
DIO in hearts from both WT and MCD
/ mice.
As discussed, it has been hypothesized that an acceler-
ation of skeletal muscle fatty acid -oxidation has the
potential to ameliorate insulin resistance by preventing the
cytosolic accumulation of fatty acid metabolites (9,10).
These ﬁndings are of particular importance because this
hypothesis has been extrapolated to cardiac muscle,
where it is proposed to attenuate myocardial dysfunction
in the failing heart (16,17,20). Thus, it was initially antici-
pated that MCD
/ mice would accumulate intramuscular
lipid and become insulin resistant and that this would be
exacerbated by DIO. However, this was clearly not the
case because MCD
/ mouse hearts were highly insulin
sensitive and protected against insulin resistance in re-
sponse to DIO. We also show that although MCD
/ mice
accumulate intramyocardial long-chain acyl CoAs in re-
sponse to DIO, this accumulation is not exacerbated
compared with that seen in WT mice. The intramyocardial
content of ceramides was not affected by either fasting or
DIO in hearts obtained from WT or MCD
/ mice. The lack
of alteration in myocardial ceramide content may be
related to the dynamic nature of this sphingolipid pool, the
size of which is determined by its rates of both synthesis
and degradation (35). The aforementioned effects are
likely attributable to the partitioning of intracellular fatty
acid intermediates into the triacylglycerol pool in hearts
from MCD
/ mice following both fasting and DIO.
Despite the increase in myocardial triacylglycerol in
hearts from MCD
/ mice following DIO, myocardial
insulin sensitivity was preserved, evidenced from the
insulin-stimulated increase in myocardial glucose oxida-
tion compared with hearts from WT mice following DIO.
These ﬁndings support recent work in skeletal muscle
suggesting that triacylglycerol accumulation may not be a
mediator of insulin resistance, but may actually serve as a
buffer against other potential lipid mediators of insulin
resistance, such as ceramide and diacylglycerol (36,37).
Further support for this concept lies in the athletes’
paradox, in which endurance-trained individuals have
greater muscle insulin sensitivity despite greater levels of
intramuscular triacylglycerols (38,39). Although no
J.R. USSHER AND ASSOCIATES
DIABETES, VOL. 58, AUGUST 2009 1773changes in ceramide were observed in hearts from
MCD
/ mice following DIO, it may be possible that the
increase in myocardial triacylglycerol buffered against the
build up of diacylglycerol in MCD
/ mice. A recent study
also demonstrates that acute inhibition of MCD in human
skeletal muscle cells via an siRNA approach decreases
fatty acid uptake and oxidation, effects that are accompa-
nied by a concomitant increase in glucose uptake and
oxidation (14). Previous work from our laboratory dem-
onstrates that the acute inhibition of MCD with novel MCD
inhibitors and the genetic deletion of MCD also causes a
metabolic shift in myocardial substrate preference toward
increased glucose oxidation and improves the recovery of
myocardial function following ischemia reperfusion
(40,41).
The results of this study are in direct contrast to a recent
study published by Essop et al. (42) showing that insulin
sensitivity was higher in mice deﬁcient for acetyl CoA
carboxylase 2 (ACC2
/). ACC2 produces malonyl CoA
from acetyl CoA, hence ACC2
/ mice have lower malonyl
CoA levels, and based on the Randle cycle should have
decreased glucose oxidation rates at the expense of ele-
vated fatty acid oxidation rates. Interestingly, ACC2
/
mice have elevated glucose and fatty acid oxidation rates
and an increased insulin-stimulated 2-deoxyglucose up-
take. However, it should be noted in this study that the
reported glucose oxidation rates are 10- to 20-fold lower
than what is normally reported in the literature and the
change in fatty acid oxidation rates is very minimal,
showing a smaller difference versus the fatty acid oxida-
tion rates between WT and MCD
/ mice reported in our
study.
In regards to AMPK, it has been shown to undergo
alterations in both the muscle and hypothalamus following
DIO and may account for some of the metabolic changes
that take place in response to DIO caused by an impaired
response to leptin (43). Despite these ﬁndings, our results
show no difference between AMPK phosphorylation in WT
and MCD
/ DIO hearts; we have also shown previously
that leptin does not activate AMPK in isolated perfused
working rat hearts (44), suggesting that leptin is likely not
mediating an effect on AMPK to alter glucose metabolism
in this study.
In conclusion, these ﬁndings demonstrate that DIO
results in an impaired cardiac insulin sensitivity, which is
not correlated with the accumulation of cytoplasmic lipid
intermediates. MCD deﬁciency prevents this impairment
independent of lipid accumulation. The beneﬁcial effects
of MCD deﬁciency on improving insulin sensitivity corre-
late with a decrease in incomplete fatty acid oxidation.
Thus, inhibition of mitochondrial fatty acid uptake via
MCD inhibition represents a novel mechanism for treating
many of the detrimental conditions associated with DIO.
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